@article{112e6827139046b7a89ebbd0c774cd2a,
title = "Chemotherapy - A viable partner for cancer immunotherapy?",
author = "Emens, {Leisha A.}",
note = "Funding Information: receives research funding or material support from Genentech/Roche, EMD Serono, Merck, Amplimmune, and Maxcyte. She has served as a consultant for Bristol Myers Squibb, Celgene, Vaccinex, Aveo, Aduro Biotech, and Astrazeneca. Under a licensing agreement between Aduro Biotech and the Johns Hopkins University, the University and Dr Emens are entitled to milestone payments and royalty on sales of the vaccine product described in the presentation. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. No other conflicts are reported. Funding Information: Dr Emens receives research funding or material support from Genentech/Roche, EMD Serono, Merck, Amplimmune, and Maxcyte. She has served as a consultant for Bristol Myers Squibb, Celgene, Vaccinex, Aveo, Aduro Biotech, and Astrazeneca. Under a licensing agreement between Aduro Biotech and the Johns Hopkins University, the University and Dr Emens are entitled to milestone payments and royalty on sales of the vaccine product described in the presentation. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. No other conflicts are reported. This work was supported in part by the Breast Cancer Research Foundation and the Commonwealth Foundation.",
year = "2015",
month = nov,
doi = "10.1001/jamaoncol.2015.2733",
language = "English (US)",
volume = "1",
pages = "1095--1097",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "8",
}